Investment Rating - The report maintains a positive outlook on the insomnia treatment market, highlighting the potential for new drug sales performance in this sector [20][32]. Core Insights - The insomnia treatment market in China is characterized by a significant unmet need, with over 200 million individuals estimated to suffer from insomnia symptoms, representing a large consumer market potential [16][24]. - The report emphasizes the shift towards innovative insomnia medications, particularly focusing on new types of benzodiazepine receptor agonists (BZRAs) and dual orexin receptor antagonists (DORAs) as key areas for development [25][38]. - The introduction of new drugs like JY-202 (地达西尼) and DORA medications is expected to reshape the market dynamics, with a forecasted rapid increase in market share and sales [34][39]. Market Overview - The insomnia drug market in China has seen stagnant growth due to a lack of new effective treatments, with the market size in 2023 estimated at 31.62 billion yuan [24]. - The report outlines the historical sales performance of major insomnia medications, indicating a long gap since the last new product launch in 2007, which has contributed to the current market stagnation [24][25]. - The report projects a significant increase in the market size and sales for innovative insomnia drugs, particularly with the anticipated approval and market entry of new products [34][39]. Drug Development Trends - The report identifies two main directions for insomnia drug innovation: improvements on existing BZRAs and the development of DORAs, which are expected to have lower addiction risks and better patient compliance [25][38]. - The new drug JY-202 is highlighted for its selective action on the GABAA receptor, which may reduce side effects associated with traditional insomnia medications [34]. - The report also notes the successful clinical trial results for DORAs, which have shown significant improvements in sleep quality without the risk of addiction, making them suitable for broader consumer use [38][39]. Key Players and Recommendations - The report suggests focusing on companies like 京新药业 (JY-202) and 先声药业 (DORA medications) as they are positioned to capitalize on the emerging market opportunities in insomnia treatment [34][39]. - It recommends monitoring the sales performance of these new drugs as they enter the market, particularly in the context of changing consumer behavior and increasing awareness of sleep health [20][32].

Market Overview - The Elastography Imaging Market was valued at USD 3.27 billion in 2024 and is projected to reach USD 5.88 billion by 2032, growing at a CAGR of 7.66% from 2025 to 2032 [1][8]. Growth Drivers - Increasing demand for non-invasive diagnostic procedures, especially for liver fibrosis, oncology, and musculoskeletal disorders, is significantly contributing to market growth [2]. - The U.S. Elastography Imaging Market was valued at USD 1.04 billion in 2024 and is projected to reach USD 1.84 billion by 2032, with a CAGR of 7.47% from 2025 to 2032, driven by strong healthcare infrastructure and high adoption of advanced imaging technologies [4]. Market Segmentation By Modality - Ultrasound holds a dominant market share of 70.52% in 2024, being cheaper and more portable than other imaging tools. MRI is the fastest-growing segment with a CAGR of 8.03% due to its high diagnostic accuracy [9]. By Application - The General Imaging segment dominated the market with a share of 34.80% in 2024, with breast elastography expected to witness the fastest growth during the forecast period [10]. By End-User - Hospitals represent the largest and fastest-growing segment, holding 41.30% of the market share and a CAGR of 8.05% due to established facilities and large patient quotas [11]. Regional Insights - North America accounted for 38.52% of the overall revenue share in 2024, primarily due to a developed healthcare system and high prevalence of chronic diseases [14]. - The Asia Pacific region is projected to grow at the fastest CAGR of 8.10% during the forecast period, driven by a large patient population and high prevalence of chronic diseases [15]. Recent Developments - In early 2024, Resoundant expanded MR Elastography clinical collaborations with academic hospitals in the U.S. and Europe [19]. - In March 2025, Siemens announced enhanced AI-assisted elastography analysis integrated into its ACUSON Sequoia system, improving real-time liver fibrosis staging [19].

Summary of China Healthcare Global Markets Research Industry Overview - The report focuses on the **China healthcare and pharmaceuticals sector** and discusses the outlook for 2026, emphasizing the importance of innovation for Chinese firms aiming to expand overseas [1][2]. Key Insights - **Sector Performance**: The healthcare sector has underperformed compared to the broader market, with the CSI 300 Health Care index declining by **12%** while the CSI 300 rose by **3%** from early September to early December [1]. - **Profit-Taking and Fund Rotation**: The underperformance is attributed to profit-taking and fund rotation towards AI themes rather than deteriorating fundamentals. The MSCI China Health Care index still shows a **64% YTD rise**, outperforming the **33%** rise of MSCI China [2]. - **Valuation Metrics**: The P/E ratios for the CSI 300 Health Care and MSCI China Health Care indices are at **2.2x** and **1.6x** respectively, indicating a comfortable valuation level at a five-year low [2]. Business Development (BD) Trends - **Continued Growth in BD**: The report predicts sustained growth in business development, particularly in out-licensing of Chinese molecules to overseas buyers, driven by: 1. Increased R&D investment in the pharmaceutical sector, with a **CAGR of 10%** for China, surpassing the global average of **4%** [10]. 2. Cost and efficiency advantages of Chinese firms in drug discovery and patient enrollment, being **2-3x** and **2-5x** faster than their overseas counterparts [11]. 3. Stabilization of geopolitical tensions, particularly between China and the US, which is expected to remain favorable through 2026 [11]. Market Challenges - **Domestic Market Uncertainty**: The report expresses uncertainty regarding a rebound in the domestic market, particularly for medical devices, due to unresolved channel inventory issues and tightening medical insurance expenditures, which account for **30-40%** of hospital and pharmacy revenues [17]. - **Potential Risks**: Key risks include setbacks in business development, an oversupply of IPOs affecting market liquidity, continued tightening of medical insurance, and geopolitical uncertainties [27]. Investment Opportunities - **Promising Companies**: The report identifies several companies likely to excel in 1H26, including: - **Hengrui**: Strong R&D pipeline and business development track record [26]. - **Innovent** and **BeOne**: Expected to achieve positive earnings inflection points [26]. - **Wuxi XDC**: Strong position in the ADC CRO space [26]. - **Mindray**: Anticipated benefits from tender results translating into revenue [26]. Innovations and Future Trends - **Emerging Modalities**: The report highlights the potential of RNAi-related therapies to lead the next wave of out-licensing, alongside the ongoing interest in antibody-drug conjugates and GLP-1s [20]. - **AI in Healthcare**: The potential for generative AI to transform healthcare is acknowledged, particularly in drug R&D, telehealth, and medical imaging analysis [21]. - **Commercial Health Insurance**: The introduction of new commercial health insurance is expected to drive innovative drug growth, contingent on collaboration among stakeholders [22]. Financial Performance - **Healthcare Sector Performance**: In 2025, the healthcare sector outperformed the broader market, with MSCI China Healthcare reporting a **58%** YTD surge compared to **31%** for MSCI China [30]. - **Biotech and CRO Performance**: Biotech and CRO sectors reported stronger financial results, with A-share healthcare companies showing a **2%** decline in revenue but a **2%** increase in net profit in 1H25 [32]. Conclusion - The China healthcare sector is positioned for growth driven by innovation and business development, despite facing challenges in the domestic market and potential geopolitical risks. The focus on R&D and the advantages of Chinese firms in drug development present significant investment opportunities moving forward.

Group 1 - The health consumption market is experiencing new development opportunities due to increased health awareness among residents, upgraded consumption structures, and ongoing policy benefits [2] - A "2026 Billion Brand Alliance" was established during the JD Health Business Merchant Conference, aimed at expanding the government-enterprise market for its partners [2] - The CEO of JD Health emphasized that "employee health is corporate productivity," indicating a shift in corporate health management from a welfare option to a key pillar of organizational development [2] Group 2 - The digital procurement ecosystem is enabling precise matching and efficient connection between supply and demand in the corporate health consumption market [3] - Digital procurement platforms are breaking down information barriers, allowing quality health consumption suppliers to directly reach corporate demand, particularly benefiting small and medium-sized health enterprises [3] - Companies are utilizing digital tools to accurately capture employee health needs, achieving personalized health benefit procurement [3]

Core Viewpoint - The article discusses the strategic shift of numerous instrument companies establishing operations in Hainan Free Trade Port, driven by the upcoming full island closure and favorable policies such as zero tariffs and simplified customs procedures [3][4]. Group 1: Instrument Companies' Movement to Hainan - Multiple instrument companies have set up branches in Hainan, including notable firms like杰莱美, 瑞赛司, and 迈瑞医, with establishments planned from 2021 to 2025 [6][7]. - Leading scientific instrument companies, such as Thermo Fisher, are accelerating their strategic layouts in Hainan by establishing collaborative innovation laboratories and research centers [7]. Group 2: Benefits of Hainan Free Trade Port - The Hainan Free Trade Port's zero-tariff policy is a key attraction, with the number of zero-tariff items expanding from over 1,900 to more than 6,600, covering 74% of all product categories, including medical devices and precision instruments [9][10]. - The new policies will simplify customs processes, significantly reducing the time required for importing scientific instruments and lowering procurement costs for companies [12][13]. Group 3: Advantages for Scientific Instrument Companies - The closure of Hainan will enhance operational efficiency for scientific instrument companies by streamlining customs procedures and reducing the complexity of import documentation [12][13]. - The expansion of zero-tariff categories will lower one-time procurement costs and long-term operational burdens, facilitating equipment upgrades and technological advancements [12][13]. - The influx of scientific instrument and medical device manufacturers will create a clustering effect, promoting domestic production and innovation in high-end research instruments [12][13]. Group 4: Export Opportunities for Domestic Instruments - Domestic instruments exported from Hainan can benefit from zero-tariff treatment on imported components, reducing manufacturing costs and enhancing profitability through a 15% corporate income tax reduction [16]. - The policies also encourage foreign instrument manufacturers to establish local production in Hainan, allowing them to benefit from favorable trade conditions when exporting or selling to the mainland [16]. Group 5: Conclusion - The full closure of Hainan is viewed as a new starting point for industrial advancement, with leading companies' concentration in the region highlighting the potential for technological development and market expansion [18].

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...

Core Insights - The National High-Performance Medical Device Innovation Center released the "2025 Medical Device Industry Innovation Ecosystem Insights" list, highlighting emerging companies, institutions, individuals, and products in China's medical device industry [1] - The assessment covers the entire chain from technology research and development to market application, showcasing the innovative ecosystem of China's medical device industry for 2025 [1] Group 1: Assessment Framework - The evaluation system has evolved from a dual dimension of "companies + individuals" to a comprehensive framework covering seven dimensions, including companies, individuals, products, universities, hospitals, investment institutions, and industrial parks [2] - This comprehensive assessment network achieves full coverage of the innovation chain, industrial chain, and capital chain [2] Group 2: Achievements and Innovations - Over the past five years, the center has made significant breakthroughs in key technologies, including the world's first 5.0T whole-body MRI and the first domestic ECMO, positioning these innovations among the international top tier [2] - The center has completed the domestic manufacturing of ECMO within three years, achieving performance metrics on par with international counterparts, marking a significant milestone in the development of high-end medical equipment in China [2] Group 3: Technological Advancements - The center is focused on strengthening core components and key raw materials, achieving full-chain domestic production for high-performance AFE chips and high-precision medical nickel-titanium materials [3] - In the past five years, the center has undertaken over 120 national and local research tasks, filed 296 patents (with two-thirds being invention patents), and participated in the revision of 11 industry standards [3] Group 4: Strategic Contributions - The center has played a pivotal role in strategic research and planning, contributing to over 30 strategic studies and deeply engaging in the national high-end medical equipment "14th Five-Year" top-level strategic planning [3] - It provides substantial intellectual support for national strategies, government decision-making, industrial resource collaboration, and corporate strategic layout [3]

12月18日，京东健康企业业务商家大会暨2026年亿元品牌联盟成立仪式在京举行。大会围绕"以力聚新，同心共健"主题， 与参会嘉宾共同就企业健康消费市场的发展机遇、数字化升级路径、阳光采购生态共建等方向，深入探讨如何通过供应链合 力，来为企业客户带来更优质、便捷、全面的健康产品与服务体验。 京东集团SEC委员、京东健康CEO曹冬在致辞中指出，"员工健康即是企业生产力"已成为广泛共识，企业健康管理正从福 利选项演进为组织发展的关键基石。京东健康依托京东集团超千亿的企业市场规模和百万级客户基础，以及自身具有的"超级 医药供应链"能力，致力于成为企业健康消费领域最值得信赖的首选合作企业。 2025年，京东健康表现强劲，营收与盈利实现双增长，合作商家数量已突破15万家。京东健康企业业务合作品牌超过800 个，其中在企业端市场，销售额千万级以上合作品牌达20余个，百万级以上合作品牌超200个，呈现出高质量增长态势。 京东集团副总裁、政企业务总裁李永明在分享中指出，京东深耕政企采购行业超十年，服务超800万家政企客户，其中涵 盖3万多家大型企业，为品牌商构筑广阔增长空间。今年以来，营养、保健、滋补、医疗器械等健康品类在政企 ...

Group 1: Pharmaceutical Sector - The innovation drug sector is expected to be the main focus, with particular attention on small nucleic acid technology and its accelerated development by 2026 [1][2] - The pharmaceutical industry is driven by supply creating demand, with significant trends observed from 2018 to 2024, including breakthroughs in PD-1, ADC technology, and new generation immunotherapy [2] - Key companies to watch in the pharmaceutical sector include Heng Rui Medicine, Hansoh Pharmaceutical, China National Pharmaceutical Group, and others involved in small nucleic acid and weight loss drug development [2] Group 2: CXO and Upstream Life Sciences - The CXO sector is expected to see continued improvement in fundamentals and valuation recovery, with a focus on companies like WuXi AppTec and Kanglong Chemical [3] - Upstream life sciences are benefiting from improved domestic research conditions, with companies like BGI Genomics and Bidu Pharmaceutical showing positive performance trends [3] - The raw material drug sector is entering a bottom price range, with companies that have quality clients and orders likely to see improved profit margins [3] Group 3: Medical Devices - The medical device sector is anticipated to benefit from improved hospital demand and inventory optimization, with a potential turning point in 2026 [4] - High-value consumables are expected to gain from collective procurement, enhancing domestic production capabilities [4] - Key players in the medical device sector include Mindray Medical, United Imaging Healthcare, and others [4] Group 4: Healthcare Consumption - The healthcare service sector is under pressure in 2025, but a mild recovery is expected in 2026, particularly in essential medical services and products [5] - Traditional Chinese medicine is projected to stabilize and grow, with a focus on OTC and prescription drug innovations [5] - The pharmacy sector is experiencing increased concentration due to regulatory changes, with companies like Yifeng Pharmacy and Dazhong Pharmacy showing improved performance [5]

Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcased over 1,000 innovative products from more than 300 leading global pharmaceutical and medical device companies, covering the latest achievements in high-end medical devices, innovative drugs, and AI applications [1] - The exhibition featured ten major exhibition areas, including medical imaging, emergency rescue, rehabilitation, and artificial intelligence, creating a comprehensive platform for display, communication, and collaboration within the pharmaceutical and medical device industry [1] - The event was organized by the China Medical Equipment Association, the National High-Performance Medical Device Innovation Center, and the Shenzhen Medical Device Industry Association [1] Group 2 - The exhibition highlighted advancements in future medical technologies, such as robotic surgery, advanced imaging equipment, brain-machine interfaces, and AI-assisted rehabilitation tools, demonstrating the potential of these innovations [2] - Notable products included the multi-port and single-port laparoscopic surgical robots from Qingfeng Medical, and an AI-based drug-device research public service platform from Particle Technology, which significantly reduces traditional research and development timelines [2] - Major companies like Mindray and Siemens showcased their cutting-edge medical equipment, emphasizing the clinical applications and enhanced imaging capabilities of their products [2] Group 3 - The pharmaceutical and medical device industry in Shenzhen has seen continuous growth, with an industry output value reaching 157.6 billion yuan in 2024, including over 102.8 billion yuan from medical devices, maintaining the top position in the country for ten consecutive years [3] - Shenzhen has nurtured 35 listed companies and 143 enterprises with an output value exceeding 100 million yuan in the pharmaceutical and medical device sector, with leading firms such as Mindray and Xintai emerging in various market segments [3] - The exhibition served as a platform for the release of significant collaborations and innovations, including a $1.64 billion strategic partnership between Pruijin and Kite for in vivo CAR-T therapies, showcasing the global push for cell therapy technologies [3]